Partner with us to develop innovative therapeutics

We work with the world’s leading pharmaceutical companies, biotechs and academic research institutions to unlock biological insights and develop novel drug treatments.

COLLABORATIONS

Combining expertise to transform and accelerate drug discovery and development

No one business can revolutionise the way medicines are discovered and developed alone. We enable our partners to leverage the benefits and insights of the Benevolent Platform® to drive drug discovery innovation and generate novel treatments. We work across every stage of the drug discovery process from Target Identification, Molecular Design through to Clinical Development and Precision Medicine.

Target Identification Collaboration

Maximise the opportunity to find novel drug targets for disease areas of interest, working with our cross-functional team of expert technologists, data scientists and drug discovery scientists.

Chemistry & Molecular Design Collaboration

Determine the optimal drug design via our AI-augmented molecular design capabilities. We combine the power of computational chemistry and advanced AI to enable data-driven drug design.

Precision Medicine Collaboration

Identify key patient subgroups for targeted treatments using AI approaches, increasing probability of clinical success and also determine the full expanse of disease indications relevant to your drug.

PHARMACEUTICAL COLLABORATION

Our work with AstraZeneca

We are collaborating with AstraZeneca to identify novel drugs for Idiopathic Pulmonary Fibrosis (IPF) and Chronic Kidney Disease (CKD). The first novel AI-generated CKD target from the collaboration has now entered AstraZeneca’s portfolio.

chronic kidney disease Idiopathic Pulm. Fibrosis

Partner with us to develop innovative therapeutics

Target Identification Collaboration

Chemistry & Molecular Design Collaboration

Precision Medicine Collaboration

Our work with AstraZeneca

Business Partners

Academic Partners

Reach out to discuss potential partnerships